Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients
- 2 January 2026
- book chapter
- Published by Springer Nature
- Vol. 77, 223-249
Abstract
Antibody-mediated rejection (AMR) is now recognized as the primary cause of the decline of functional integrity and ultimately, graft failure in kidney transplants. Evolving understanding of effectors responsible for B-cell activation and plasma cell biology has led to the informed design of new therapeutics. Currently, several novel agents with varying mechanisms of action have emerged. These include imlifidase, FcRn inhibitors, anti-cytokine (IL-6/IL-6R) therapies, and plasma cell-directed therapies, especially anti-CD38s. As our understanding of critical effector pathways responsible for ARM grows, we now know that no single agent can control all facets of antibody generation and injury. The future of antibody-directed therapeutics will require protocols consisting of multiple agents positioned in a logical sequence to rapidly and durably remove pathogenic DSAs and block their re-emergence.Keywords
This publication has 99 references indexed in Scilit:
- Transplants foster B cell alloimmunity by relaying extracellular vesicles to follicular dendritic cellsCell Reports, 2025
- ATC 2024 Table of ContentsAmerican Journal of Transplantation, 2024
- Rozanolixizumab: First ApprovalDrugs, 2023
- Tocilizumab for antibody-mediated rejection treatment in lung transplantationThe Journal of Heart and Lung Transplantation, 2023
- Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its UseCNS Drugs, 2023
- Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapyAmerican Journal of Transplantation, 2023
- Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney AllograftsKidney International Reports, 2022
- Imlifidase: First ApprovalDrugs, 2020
- Immunomodulatory effects of CD38-targeting antibodiesImmunology Letters, 2018
- Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysisInternational Urology and Nephrology, 2013